Abstract
Rationale Racial and ethnic differences in presentation and outcomes have been reported in systemic sclerosis (SSc) and SSc-interstitial lung disease (ILD). However, diverse cohorts and additional modeling can improve understanding of risk features and outcomes, which is important for reducing associated disparities.
Objective(s) To determine if there are racial/ethnic differences associated with SSc-ILD risk and age; time intervals between SSc and ILD, and with emergency department (ED) visit or hospitalization rates.
Methods A retrospective cohort study using electronic health record data from an integrated health system, over a 5.5 year period was conducted using clinical and sociodemographic variables, models were generated with sequential adjustments for these variables. Logistic regression models were used to examine the association of covariates with ILD and age at SSc-ILD. Healthcare outcomes were analyzed with complementary log-log regression models.
Results The cohort included 756 adults (83.6% female, 80.3% non-Hispanic White) with SSc with a mean age of 59 years. Overall, 33.7% of patients in the cohort had an ILD code, with increased odds for Asian (odds ratio [OR], 2.59; 95% confidence interval [CI], 1.29, 5.18; P=.007) compared to White patients. The age in years of patients with SSc-ILD was younger for Hispanic (mean difference, −6.5; 95% CI, −13, −0.21; P = 0.04) and Black/African American patients (−10; 95% CI −16, −4.9; P <0.001) compared to White patients. Black/African American patients were more likely to have an ILD code before an SSc code (59% compared to 20.6% of White patients), and had the shortest interval from SSc to ILD (3 months). Black/African American (HR, 2.59; 95% CI 1.47, 4.49; P=0.001) and Hispanic patients (HR 2.29; 95% CI 1.37, 3.82; P=0.002) had higher rates of an ED visit.
Conclusion In this study, SSc-ILD presentation and outcomes differed by racial/ethnic group (increased odds of SSc-ILD, younger age at SSc-ILD, and preceding diagnosis with respect to SSc, rates of ED visit), some of which was attenuated with adjustment for clinical and sociodemographic characteristics. Differing presentation may be driven by social drivers of health (SDOH), autoantibody profiles, or other key unmeasured factors contributing to susceptibility and severity.
Competing Interest Statement
GMH: consulting fees- Boehringer-Ingelheim, Gerson Lehrman Group DWB: grants or contracts to institution, IBM Watson. Consulting fees- EarlySense, AESOP, FeelBetter. Patents planned, issued or pending - (PHC-028564 US PCT), on intraoperative clinical decision support. Stock or stock options - Clew, MDClone, ValeraHealth, FeelBetter, Guided Clinical Solutions
Funding Statement
National Institutes of Health T32
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Mass General Brigham gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: AMCT, JAR are supported by T32-HL0007633. GMH is supported by R01 HL111024, R01 HL130974, and R01 HL135142. The funder had no role in study design, data analysis, data interpretation nor writing of the manuscript.
Data Availability
Data is not currently publicly available but may be available upon reasonable request to the authors.
